Patient-Level Treatment Drivers in Psoriasis

Effective psoriasis (PsO) management increasingly depends on a treatment selection framework that extends beyond skin severity to encompass the full clinical and contextual profile of the individual patient. Route of administration is among the most practically influential of these factors. Some patients may express an instinctive preference for oral medications, but that preference is rarely fixed and often shifts when clinicians provide the comparative context needed to make a genuinely informed choice — including how often injections actually occur at maintenance and how that burden compares with the commitment of daily oral dosing. For a patient on a biologic with every-12-week maintenance dosing, the annual injection burden is 4 administrations; for a once-daily oral agent it is 365. Surfacing this distinction explicitly, rather than assuming patients have already weighed it, is an important part of the prescribing conversation in PsO. Patients who value minimal day-to-day treatment interaction once disease is controlled may find that a long-interval injectable biologic ultimately imposes less lifestyle burden than they anticipated.

The presence, severity, and anatomical pattern of psoriatic arthritis are among the most consequential determinants of mechanism selection in patients with psoriatic disease. IL-17 inhibitors carry the most robust data across the full spectrum of psoriatic arthritis domains — peripheral joint disease, distal interphalangeal involvement, dactylitis, enthesitis, and axial disease — and have demonstrated inhibition of radiographic progression. For patients with prominent axial psoriatic arthritis in particular, IL-17 blockade remains the preferred mechanism, supported by an evidence base that other classes have not yet matched for this specific manifestation. Within the IL-23 class, guselkumab has recently demonstrated radiographic benefit in psoriatic arthritis, meaningfully narrowing the differentiation between IL-17 and IL-23 agents for patients with distal joint involvement, though axial disease continues to favor IL-17 inhibition. Conversely, IL-17 inhibitors carry an important contraindication in patients with inflammatory bowel disease — a comorbidity not uncommon in PsO — whereas IL-23 inhibitors can be used across a considerably broader comorbidity range without meaningful restriction.

In this Special Report segment, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, describes the practical decision framework he applies at the point of prescribing. IL-23 inhibitors occupy a favored default position for most patients with skin-predominant disease: they offer infrequent maintenance dosing, an essentially unrestricted comorbidity profile outside of active infection, and long-term durability data that compare favorably with other biologic classes. IL-17 inhibitors are reserved primarily for patients with significant psoriatic arthritis — particularly axial disease — where the evidence for superior joint outcomes justifies accepting a more restrictive contraindication profile. Oral agents are positioned for patients who prioritize the oral route and can accept a somewhat lower efficacy ceiling than the most potent injectable biologics. This mechanism-first framework, calibrated by comorbidity and arthritis pattern before patient preference is layered on, reflects how substantively PsO treatment selection has evolved from stepwise escalation into a nuanced, multidimensional clinical decision.